Story · Medicine & Biotech

Summit Therapeutics Expands Ivonescimab Development Program With New Phase III HARMONi-10 Trial

1 outlet · first reported by OncoDaily on

While the FDA recently declined to approve ivonescimab in combination with chemotherapy for previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC), Summit Therapeutics continues to expand the drug’s clinical (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study randomized trial
    Summit Therapeutics Expands Ivonescimab Development Program With New Phase III HARMONi-10 Trial

    While the FDA recently declined to approve ivonescimab in combination with chemotherapy for previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC), Summit Therapeutics continues to expand the drug’s clinical

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.